Spruce Biosciences, Inc.

NASDAQ:SPRB

Biotechnology

Healthcare
$40.84 +5.07%

+$2.47 today

Market cap
$117.37M
Beta
3.20
P/E (TTM)
-1.9
EPS (TTM)
-$27.11
52W Low $7.00High $838.13

Volume 0.06M

Average 0.06M

SPRB Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Spruce Biosciences, Inc.NASDAQ: SPRB

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 111.1% from a year ago

Cash & equivalents stood at $54.08M at the end of Q1 FY2026, up 111.1% from a year earlier and up 10.6% from the prior quarter. Over 3 fiscal years it compounded at +25.9% a year.

Context

  • Cash & equivalents amounted to 96.3% of total assets at the end of Q1 FY2026, up 15.4 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +111.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$54.08M+10.6% QoQ
Last fiscal yearDec 2025
$48.91M+26.2% YoY
Year agoMar 2025
$25.62M+111.1% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+111.1%——
1 year+26.2%——
3-year CAGR+25.9%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
48.91M USD
Year-over-year change
+26.2%
4-year CAGR
+3.4%

Cash & Equivalents vs competitors

How SPRB compares with its peers on the latest reported figures

  • SPRB's Mar 2026 cash & equivalents of $54.08M is the 4th highest of the 9 companies compared; the peer median is $19.18M.
  • Its year-over-year change of +111.1% is the 4th highest of 9, against a peer median of +23.4%.
  • Cash & equivalents amounts to 96.3% of total assets for SPRB, versus a peer median of 73.7%.
SPRB Competitors Peer median
Cash & Equivalents for SPRB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OSTXOS Therapies IncorporatedMar 2026$917.55M +30783.5%+1063.1%12570.5%
VTVTvTv Therapeutics Inc.Mar 2026$98.09M +215.8%+94.3%99.3%
EQEquillium, Inc.Mar 2026$61.32M +322.9%-20.0%97.2%
SPRBSpruce Biosciences, Inc.Mar 2026$54.08M +111.1%+25.9%96.3%
HOWLWerewolf Therapeutics, Inc.Jun 2026$21.99M -71.7%-23.5%91.0%
CUECue Biopharma, Inc.Mar 2026$16.38M +24.7%-19.3%53.0%
OTLKOutlook Therapeutics, Inc.Mar 2026$7.75M +2.5%-22.5%35.4%
NRXPNRx Pharmaceuticals, Inc.Mar 2026$6.71M +21.0%-27.0%56.4%
COEPCoeptis Therapeutics, Inc.Mar 2026$5.21M +22.1%+14.4%26.3%
Peer median (excluding SPRB) $19.18M+23.4%-19.6%73.7%

Competitors are the stored peer set for SPRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents42.75M24.49M96.34M38.75M48.91M
Short-term Investments46.22M54.59M000
Net Receivables00000
Inventory00000
Other Current Assets396K1.21M1.97M2.28M2.85M
Total Current Assets91.9M83.61M102.18M44.21M52.11M
Property, Plant & Equipment (Net)1.48M1.4M1.18M934K666K
Goodwill00000
Intangible Assets00000
Long-term Investments32.46M(54.54M)0036K
Tax Assets00000
Other Non-current Assets653K55.18M582K69K207K
Total Non-current Assets34.59M2.04M1.76M1M909K
Total Assets126.49M85.65M103.95M45.21M53.02M
Account Payables2.82M1.43M3.33M1.3M943K
Short-term Debt01.62M1.62M1.62M0
Tax Payables00000
Deferred Revenue004.91M00
Other Current Liabilities1.44M1.29M11.25M882K1.77M
Total Current Liabilities8.87M12.45M24.47M15.25M10.09M
Long-term Debt4.88M3.29M1.72M124K419K
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities73K161K236K282K0
Total Non-current Liabilities6.24M4.72M2.97M1.14M419K
Total Liabilities15.12M17.16M27.44M16.39M10.51M
Common Stock3K3K4K4K0
Retained Earnings(103.13M)(149.31M)(197.23M)(250.27M)(289.23M)
Accumulated OCI(184K)(558K)000
Other Stockholders Equity00000
Minority Interest00000
Total Equity111.37M68.49M76.51M28.82M42.52M
Total Debt6.53M6.32M4.61M2.77M736K
Net Debt(36.22M)(18.17M)(91.73M)(35.99M)(48.17M)

Spruce Biosciences, Inc.

NASDAQ:SPRB

Intrinsic Alpha fair value

Locked

Current Price

$40.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.